12/07/2022 - General information
This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
04/07/2022 - Covid-19
The possibility of re-freezing vials once they are prepared may enable the manipulation of vaccines in the country of origin, freezing the syringes, and sending them to their destination for immediate use, without the need for a major infrastructure. The shelf life of the re-frozen vaccine is at least one month.
07/07/2022 - Covid-19
A study on the vaccine response of patients with primary antibody deficiency carried out by the Functional Unit of Primary Immunodeficiencies at Hospital del Mar together with the dibi Network (Reference Laboratory of Catalonia) has revealed that a good number of these people have antibodies against SARS-CoV-2 without actually having contracted COVID-19. The study, published in the journal Immunology, is the first to certify the transmission of antinucleocapsid antibodies (ANC) from donors to patients with primary immunodeficiency.
28/06/2022 - General information
This is a study on the impact of the COVID-19 pandemic on the breast cancer screening program. Its main author is Dr. Guillem Bosch, resident physician of the PSMAR-UPF-ASPB Teaching Unit and member of the Health Services Research Group of the Hospital del Mar Medical Research Institute.
17/06/2022 - Institutional news
IMIM-Hospital del Mar is committed to attracting scientific talent of excellence and young researchers through IMIM-OpenLAB. The initiative provides fully equipped facilities and young scientists who choose to take advantage of this opportunity are guaranteed initial funding. The centre has set up a new laboratory area with the intention of facilitating transversal and multidisciplinary work and promoting the incorporation of new researchers who are committed to undertaking or continuing their research in the biomedical cluster comprising the IMIM, Hospital del Mar and the PRBB environment. A space in which the Immune Redirection Research Group is already at work, focusing on the identification of specific alterations in tumour cells that can be used as therapeutic targets for new anti-cancer treatments, such as immunotherapy.
Més informació "IMIM-Hospital del Mar's cutting-edge research is strengthened"
17/06/2022 - Institutional news
The Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research, have awarded Dr. Edurne Arriola more than 8,000 euros to boost immunotherapy and lung cancer research being carried out at Hospital del Mar and the Hospital del Mar Medical Research Institute. Lung cancer research at Hospital del Mar and the Hospital del Mar Medical Research Institute has received a new boost thanks to the Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research. The two organisations have managed to raise 8,000 euros, which will be used to support the work of researchers in this field.
14/06/2022 - General information
It is published by Triacastela Publishing House. In it, Dr. Porta explains, in an easy and entertaining way, current epidemiological and public health issues, such as the management by governments of the COVID-19 pandemic. Epidemiology and epidemiologists have been in vogue over the last two years, when SARS-CoV-2 and COVID-19 have made all the headlines. A medical and scientific discipline that studies and acts on populations and groups of people under real conditions, which is carried out outside laboratories.
Més informació "Epidemiología cercana, the new book by Dr. Miquel Porta"
31/05/2022 - Institutional news
The hospital is the only healthcare centre in Spain to form part of the group behind the project, which aims to create a mobile app platform to personalise patient monitoring for sufferers of this disease. The initiative will receive funding from the EU's HORIZON programme. Hospital del Mar's Pneumology Department is part of the TOLIFE project (Artificial Intelligence and Smart sensing TOward better management and improved quality of LIFE in chronic obstructive pulmonary disease). This is an international initiative to develop a tool that, using artificial intelligence, will improve and personalise the treatment of patients with chronic obstructive pulmonary disease (COPD).
30/05/2022 - Press release
A group of genes has been identified in cancerous cells that survive chemotherapy treatment. The activity of these genes leads to treatment resistance and increased capacity for metastasis. This breakthrough opens the door to studying targeted treatments using drug inhibitors of these genes combined with chemotherapy, potentially providing alternatives for patients with a worse prognosis in this type of tumor, accounting for 30% of cases. The research, led by scientists from the Hospital del Mar Medical Research Institute, highlights that this type of tumor cell reverts to an embryonic state. Identifying the factor that triggers this change could aid in designing new treatments for high-risk patients.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact